Foundry Healthcare 6-Month Momentum Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1HUM | HUMANA INC | Healthcare | $48.02B | 11.44% |
2RVMD | REVOLUTION MEDICINES INC | Healthcare | $39.58B | 9.42% |
3CNC | CENTENE CORP | Healthcare | $32.81B | 7.81% |
4ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 5.91% |
5MRNA | MODERNA INC | Healthcare | $24.53B | 5.84% |
6DVA | DAVITA INC | Healthcare | $15.21B | 3.62% |
7BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $13.71B | 3.26% |
8APGE | APOGEE THERAPEUTICS INC | Healthcare | $10.10B | 2.41% |
9CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 2.31% |
10ALKS | ALKERMES PLC | Healthcare | $8.79B | 2.09% |
11OSCR | OSCAR HEALTH INC | Healthcare | $8.77B | 2.09% |
12SYRE | SPYRE THERAPEUTICS INC | Healthcare | $8.70B | 2.07% |
13TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 2.00% |
14IBRX | IMMUNITYBIO INC | Healthcare | $8.04B | 1.92% |
15LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 1.69% |
16LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 1.67% |
17HNGE | HINGE HEALTH INC | Healthcare | $6.74B | 1.60% |
18CGON | CG ONCOLOGY INC | Healthcare | $6.34B | 1.51% |
19LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 1.45% |
20ERAS | ERASCA INC | Healthcare | $5.96B | 1.42% |
21TWST | TWIST BIOSCIENCE CORP | Healthcare | $5.84B | 1.39% |
22DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.77B | 1.37% |
23ORKA | ORUKA THERAPEUTICS INC | Healthcare | $5.59B | 1.33% |
24TXG | 10X GENOMICS INC | Healthcare | $5.55B | 1.32% |
25DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.83B | 1.15% |
26EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $4.28B | 1.02% |
27TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.13B | 0.98% |
28RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 0.91% |
29DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.70B | 0.88% |
30ALMS | ALUMIS INC | Healthcare | $3.65B | 0.87% |
31OGN | ORGANON & CO | Healthcare | $3.55B | 0.85% |
32ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.24B | 0.77% |
33ACHC | ACADIA HEALTHCARE COMPANY INC | Healthcare | $3.17B | 0.76% |
34MBX | MBX BIOSCIENCES INC | Healthcare | $2.99B | 0.71% |
35QURE | UNIQURE NV | Healthcare | $2.54B | 0.60% |
36ASTH | ASTRANA HEALTH INC | Healthcare | $2.50B | 0.60% |
37SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $2.45B | 0.58% |
38NKTR | NEKTAR THERAPEUTICS | Healthcare | $2.31B | 0.55% |
39AGL | AGILON HEALTH INC | Healthcare | $2.17B | 0.52% |
40PLSE | PULSE BIOSCIENCES INC | Healthcare | $1.98B | 0.47% |
41ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 0.47% |
42URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.47% |
43MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.45% |
44BCAX | BICARA THERAPEUTICS INC | Healthcare | $1.82B | 0.43% |
45BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.73B | 0.41% |
46MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $1.72B | 0.41% |
47ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.40% |
48CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.67B | 0.40% |
49PSNL | PERSONALIS INC | Healthcare | $1.61B | 0.38% |
50VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 0.38% |
51NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.38% |
52INNV | INNOVAGE HOLDING CORP | Healthcare | $1.56B | 0.37% |
53AVBP | ARRIVENT BIOPHARMA INC | Healthcare | $1.55B | 0.37% |
54AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.36B | 0.32% |
55ABSI | ABSCI CORP | Healthcare | $1.29B | 0.31% |
56CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $1.25B | 0.30% |
57DRTS | ALPHA TAU MEDICAL LTD | Healthcare | $1.19B | 0.28% |
58AVNS | AVANOS MEDICAL INC | Healthcare | $1.17B | 0.28% |
59ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.28% |
60MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.27% |
61CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $1.09B | 0.26% |
62BIOA | BIOAGE LABS INC | Healthcare | $1.01B | 0.24% |
63SLDB | SOLID BIOSCIENCES INC | Healthcare | $859M | 0.20% |
64AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $823M | 0.20% |
65ACRS | ACLARIS THERAPEUTICS INC | Healthcare | $793M | 0.19% |
66ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.18% |
67CADL | CANDEL THERAPEUTICS INC | Healthcare | $746M | 0.18% |
68CLYM | CLIMB BIO INC | Healthcare | $727M | 0.17% |
69TECX | TECTONIC THERAPEUTIC INC | Healthcare | $615M | 0.15% |
70STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.14% |
71FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.14% |
72IMMX | IMMIX BIOPHARMA INC | Healthcare | $558M | 0.13% |
73NVCT | NUVECTIS PHARMA INC | Healthcare | $508M | 0.12% |
74XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.12% |
75CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.10% |
76STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.09% |
77ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.09% |
78MASS | 908 DEVICES INC | Healthcare | $278M | 0.07% |
79TTRX | TURN THERAPEUTICS INC | Healthcare | $272M | 0.06% |
80QTTB | Q32 BIO INC | Healthcare | $255M | 0.06% |
81ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.06% |
82IMUX | IMMUNIC INC | Healthcare | $207M | 0.05% |
83BDSX | BIODESIX INC | Healthcare | $204M | 0.05% |
84FOCL | FOCAL INC | Healthcare | $204M | 0.05% |
85DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.05% |
86AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.05% |
87KRRO | KORRO BIO INC | Healthcare | $177M | 0.04% |
88PMN | PROMIS NEUROSCIENCES INC | Healthcare | $136M | 0.03% |
89CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.03% |
90CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $103M | 0.02% |
91ICCC | IMMUCELL CORP | Healthcare | $101M | 0.02% |
92LIXT | LIXTE BIOTECHNOLOGY HOLDINGS INC | Healthcare | $91M | 0.02% |
93RLYB | RALLYBIO CORP | Healthcare | $87M | 0.02% |
94NRXS | NEURAXIS INC | Healthcare | $84M | 0.02% |
95PIII | P3 HEALTH PARTNERS INC | Healthcare | $78M | 0.02% |
96NMAD | NOMAD POWER SOLUTIONS INC | Healthcare | $72M | 0.02% |
97EDSA | EDESA BIOTECH INC | Healthcare | $59M | 0.01% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $419.92B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 91% toward Large, 53% toward Growth. +4% unclassified (9 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 97 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 97 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 55.5% | 13.9% |
| 3 yearsp.a. | 20.3% | 12.6% |
| 5 yearsp.a. | 13.2% | 16.3% |
| 10 yearsp.a. | 18.8% | 14.6% |
| Since inceptionp.a. | 14.2% | 4.0% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 17.8% | 24.8% |
| 2025 | 39.0% | 23.0% |
| 2024 | 10.4% | 4.6% |
| 2023 | -2.9% | -28.9% |
| 2022 | -4.3% | 31.8% |
| 2021 | 37.2% | 92.9% |
| 2020 | 51.0% | 16.3% |
| 2019 | 9.6% | -40.8% |
| 2018 | 2.5% | 25.6% |
| 2017 | 50.3% | 44.5% |
| 2016 | -14.7% | 13.1% |
| 2015 | 4.6% | -13.3% |
| 2014 | 13.6% | -15.7% |
| 2013 | 62.0% | 23.1% |
| 2012 | 14.8% | -9.5% |
| 2011 | 17.4% | 30.2% |
| 2010 | 11.5% | -12.4% |
| 2009 | 27.1% | -24.7% |
| 2008 | -17.3% | 1.2% |
| 2007 | 7.5% | -1.0% |
| 2006 | -2.0% | -15.8% |
| 2005 | 30.1% | 14.2% |
| 2004 | -1.9% | -15.1% |
| 2003 | 41.3% | 13.3% |
| 2002 | -34.6% | -27.6% |
| 2001 | -10.2% | -7.9% |
| 2000 | 38.5% | 9.2% |
| 1999 | 65.6% | 52.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare 6-Month Momentum Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a 6-Month Momentum signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.